STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 01 March 2004 please refer to module 8B. 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Notification/ 
Opinion issued 
on2 
20.10.99 
Commission 
Decision 
Issued/amended 
on 
15.12.99 
14.12.00 
23.04.01 
14.12.00 
18.05.01 
13.12.2001 
02.04.02 
08.05.02 
17.05.02 
19.09.02 
19.12.02 
30.07.02 
- 
30.07.02 
09.09.02 
30.07.02 
30.07.02 
30.07.02 
15.01.03 
- 
- 
- 
17.02.03 
I/0001 
II/0002 
S/0003 
II/0004 
I/0005 
II/0006 
I/0007 
I/0008 
I/0009 
I/0010 
I/0011 
N/0012 
I 
II 
S 
II 
I 
II 
I 
I 
I 
I 
I 
N 
Change  in  supplier  of  an  intermediate  compound  used  in 
manufacture of the active substance 
Update  of  Summary  of  Product  Characteristics  (SPC)  and 
Package  Leaflet  (PL)  sections  “Therapeutic  indications”, 
“Special  Warnings  and  special  precautions  for  use”,” 
Interaction  with  other  medicinal  products  and  other  forms 
of interactions”, “Undesirable effects”, “Pharmacodynamic 
properties”),  following  the  annual  reassessment  of  the 
benefit/  risk  profile,  the  evaluation  of  PSUR  6  and  the 
availability of new safety data 
Annual reassessment 
All remaining specific obligations are fulfilled, there are no 
remaining  grounds  to  keep  the  Marketing  Authorisation 
under exceptional circumstances 
Update of the SPC, (sections “Special warnings and special 
precautions 
for  use”,  “Pharmacodynamic  properties”) 
following the availability of new clinical data in paediatric 
patients  with  hepatitis  B.  Furthermore,  the  MAH  proposed 
some minor changes in the SPC, Labelling and PL in order 
to  bring  the  text  in  line  with  the  latest  QRD/  EMEA 
templates.  The  MAH  also  included  changes  to  the  name/ 
address of the local representatives.  
Change  in  specification  of  starting  material/intermediate 
used in manufacturing of the active substance 
Update  of  the  SPC  in  order  to  provide  prescribers  with 
available  information  on  the  exacerbation  of  hepatitis, 
either  upon  treatment  discontinuation  or  due  to  loss  of 
efficacy  with  Zeffix.  Also,  to  update  information  on  the 
occurrence  of  YMDD  variant  HBV  in  patients  receiving 
long-term  therapy.  Finally  to  include  5-year  results  from  a 
clinical study. 
Changes  relate  to  sections  4.4  (“Special  warnings  and 
special  precautions  for  use”)  and  5.1  (“Pharmacodynamic 
properties”) of the SPC. 
Change in or addition of manufacturing site(s) for part or all 
of the manufacturing process 
Change in or addition of manufacturing site(s) for part or all 
of the manufacturing process 
Change 
in 
packaging material 
Minor changes in manufacture of the medicinal product 
Change in the batch size of finished product 
Changes  to  aspects  of  the  PL  to revise  the  list  of  the  local 
representatives and to correct the name of the manufacturer 
and to the Labelling to add the name of active ingredient to 
the  blister  foil.  Furthermore  this  notification  amends  the 
Danish,  French,  Italian  and  Swedish  language  versions  of 
the  PL  to  correctly  reflect  the  English  version.  At  this 
occasion  the  texts  of  the  Labelling  and  PL  have  been 
amended in line with the EMEA/QRD templates. 
Change in test procedure of active substance 
the  qualitative  composition  of 
immediate 
I/0014 
I 
05.08.2003 
19.08.2003 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) 
No 2141/96 of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
1/2 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
                                                      
 
Update  of  the  SPC  further  to  the  CPMP  assessment  of  the 
PSUR covering 1 June - 30 November 2002. This includes 
reformatting  section  4.8  "Undesirable  effects",  presenting 
the adverse drug reactions by MedDRA system organ class 
and  ranked  by  frequency  and  adding  the  adverse  reactions 
thrombocytopenia and muscle disorders, including myalgia 
and cramps. Furthermore, the SPC has been updated in line 
with the latest EMEA/QRD templates. 
The  PL  has  been  updated  accordingly.  Furthermore,  the 
name of manufacturer has been corrected in the Danish PL. 
Change 
control/testing site 
in  BR/QC 
testing  – 
repl./add.  Of  batch 
Minor  change  in  the  manufacturing  process  of  the  active 
substance 
II/0015 
II 
22.10.2003 
awaited 
I/0016 
IB/0022 
I 
I 
29.10.2003 
10.02.2004 
- 
- 
2/2 
EMEA 2005 
 
 
 
 
 
 
 
